How Low Does PSA Need to Go in Metastatic Prostate Cancer?

https://www.medscape.com/viewarticle/how-low-does-psa-need-go-metastatic-prostate-cancer-2026a1000rpa?ecd=WNL_trdalrt_pos1_ous_260817_etid8604317&uac=148436CN&impID=8604317 A real-world analysis suggests that achieving a prostate-specific antigen (PSA) level < 0.2 ng/mL within 9 months of starting androgen deprivation therapy (ADT)-based treatments was the PSA benchmark most consistently associated with improved overall survival in men with metastatic castration-sensitive prostate cancer. Achieving a PSA level < 0.2 ng/mL within 9 months of ADT initiation was associated with a significantly lower subsequent risk for death, while achieving 90% or greater PSA decline but not a PSA level < 0.2 ng/mL was not tied to improved overall survival.